

Inventors: Border and Ruoslahti
Serial No.: 08/349,479
Filed: December 2, 1994
Page 2

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-20 (canceled)

KL
m
Claim 21: (previously presented) A method of decreasing the deleterious accumulation of extracellular matrix associated with a pathology or a condition wherein TGF- β -induced production and deleterious accumulation of extracellular matrix in a tissue exists comprising:

contacting the tissue with an anti-TGF- β antibody that binds to TGF- β ;
whereby the binding of the anti-TGF- β antibody to the TGF- β suppresses the deleterious accumulation of the TGF- β -induced extracellular matrix in the tissue, and wherein the pathology or condition is glomerulonephritis.

Claims 22-34 (canceled)

Inventors: Border and Ruoslahti
Serial No.: 08/349,479
Filed: December 2, 1994
Page 3

K2
M2
Claim 35: (new) A method for treating a pathology characterized by an accumulation of extracellular matrix in a tissue, comprising contacting said tissue with a TGF-beta suppressing agent which suppresses the extracellular matrix producing activity of TGF-beta, wherein said pathology is adult respiratory distress syndrome and wherein said agent is an TGF-beta antibody.
